[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
January 12, 2016

Bronchoscopic Lung Volume Reduction in COPDLessons in Implementing Clinically Based Precision Medicine

Author Affiliations
  • 1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA. 2016;315(2):139-141. doi:10.1001/jama.2015.17714

Consistent with strategies across many traditionally defined diseases and syndromes, research efforts in chronic obstructive pulmonary disease (COPD) have attempted to identify meaningful subclasses of disease that categorize and help identify patients who may be uniquely responsive to specific interventions. In the current context of increased interest in “precision medicine,” achieving this classification would require developing a better understanding of genetic variation and the resulting uniquely expressed cellular targets amenable to specific molecular therapeutic intervention. However, better classification of patients based on unique clinical, physiologic, and radiographic factors, rather than genetic variation, has been more effective in achieving increasingly precise clinical application of therapeutics in the context of surgical and bronchoscopic device lung volume reduction strategies.

First Page Preview View Large
First page PDF preview
First page PDF preview
×